Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Cells communicate through receptors on their surface. Diseases are triggered when these finely tuned systems don’t work correctly. We can now look at the signalling complexes down to the atomic level. This knowledge might help us develop therapies to grow nerve cells through a scar in the spinal cord, stop cancer from growing and spreading, or develop anti-cancer vaccines.

Q: Hello Yvonne. Why is cell-cell communication important for our health?

YJ: Because our bodies are made up of millions and millions of cells and they all need to be able to communicate with each other and work out: are they in the right place, doing the right thing, at the right time? Do they need to move to somewhere different? Do they need to multiply up? Do they even need to die because they are not needed anymore?

Q: What happens when the signalling systems don't work properly?

YJ: One example would be cancer. That is a case where signalling systems aren't working correctly in terms of telling cells not to just carry on growing and multiplying. The particular aspect that I am currently working on is in the latter stages of cancer - metastasis - when cancer cells start moving from that particular tissue where they have started growing to different tissues. So they are no longer staying where they should be, they are invading other parts of the body. That would be one example. Another example would be the immune system not recognising that we have been infected by particular organisms, so the immune cells aren't spotting this fact and fighting things off fast enough.

Q: Could you tell us how cells communicate?

YJ: The way that they do that is through receptors on their cell surfaces - it is like they have got lots and lots of little aerials sticking out from their surface, but in this case they are proteins and what they are doing is waiting to recognise and to dock into proteins either from neighbouring cells or that are secreted by cells. Sometimes over very long distances they build up gradients, so they're acting as messages for cells to grow or divide or, in the case of the cells that I am interested in at the moment, for metastasis for cancer cells, then they are determining this balance between whether a cell is sticking somewhere or whether it is being pushed away and moving off. They are acting as guidance queues, almost like cellular SatNav!

Q: What are the most important lines of research that have developed in the past 5 or 10 years?

YJ: In my view it would be our ability to look at these signalling systems right down to the atomic level detail. It is a bit like understanding how a clock works or how a car works - it is all very well trying to describe it in words, but if you can actually see it in detail, open up the bonnet and see inside at all the different bits of a motor, then you can understand how it works. And once you can understand how it works you have some idea of how you can go in and manipulate it to make it work correctly when things go wrong.

Q: Why does your line of research matter, why should we put money into it?

YJ: Because if we can understand what these things really look like and how therefore they work, then we can go in and either block them in the case of a cell guidance queue that is now acting to guide cells in cancer metastasis to where they shouldn't be in the body, so we want to actually block it. You could design a drug, a small molecule that would go in, fit very specifically the shape of the antennae, the little structure on the cell surface, and block it. Or else in the case of the repair of the spinal cord when there has been serious injury, there the problem is that the nerve cells aren't able to regenerate and grow through the scar. And if we can stop the signals that are stopping them and instead give them signals to encourage them to grow through the scar, then we can help regenerate after damage.

Q: How does your research fit into translational medicine within the department?

YJ: Well obviously what I am doing is very basic research but I can then discuss with my colleagues how my basic insights can feed through to the clinic, and that is one of the exciting things about being part of the Nuffield Department of Medicine. It takes a long time, but one example of something that we have been doing now for over a decade is looking at the way that the cells in the immune system are able to recognise when a cell is infected. In particular we have been looking at how they recognise cancer cells for melanoma, and that is work I'm doing with Enzo Cerundolo who is based at the Weatherall Institute of Molecular Medicine. He is a tumour immunologist, and from taking my basic insights he is now able to work to try and improve anti cancer tumour vaccines which can be given to patients when they have got melanoma as one of the ways of trying to combat it.

Yvonne Jones

Cell surface signalling complexes

Prof. Yvonne Jones is director of the Cancer Research UK Receptor Structure Research Group. Her research focuses on the structural biology of cell surface recognition and signalling complexes. Receptors embedded in the surface are potential targets for therapeutic intervention in many diseases including cancer.

More podcasts related to Cancer

Raghib Ali: INDOX Cancer Research Network

INDOX is a collaboration between Oxford and twelve leading cancer centres in India. It aims to develop effective and affordable cancer treatments in low and middle income countries, to improve the early detection of cancer, and to reduce the incidence of cancer by establishing the population specific risk factors.

Vincenzo Cerundolo: Cancer immunology

The development of therapeutic vaccines is more challenging. Current lines of research include the development of antibodies blocking inhibitory T cell signals, and the characterisation of adjuvants.

David Jackson: The Lymphatic System in Immunity and Cancer

Our lymphatic system protects us against pathogens: it collects micro-organisms and carries them to the lymph nodes where they will meet and activate T cells and B cells. Cancer cells also migrate to the lymph nodes, but instead of activating the immune system they actually suppress it. A better understanding of these mechanisms might help us better control the spread of tumours, and also block unwanted immune responses in autoimmune diseases, block tissue rejection and make vaccines more effective.

Tim Key: Role of Lifestyle and Diet in Cancer

We know that although smoking is still the most important cause of cancer, obesity and high intakes of alcohol increase the risk for several types of cancer. The role of diet in the development of cancer is much less clear, but there is a lot of evidence suggesting that diet does matter.

Patrick Pollard: Cancer Metabolism

Dr Pollard’s work is focused on a form of kidney cancer for which no effective therapy exists once it metastasizes. By integrating analyses of these cancer cells and novel models he hopes to provide insights into altered cancer metabolism and a real, innovative route into the design of therapies for various cancers.

Catherine Green: DNA replication and Cancer

The process of DNA replication is complex, and mistakes can lead to genome instability. Surveillance systems are not always successful which results in mutations that have the potential to inactivate genes or change their activity. This can lead to cancer, and many chemotherapeutic drugs are designed to disrupt DNA replication. A better understanding of these mechanisms can help us develop new drugs with reduced side effects.

Skirmantas Kriaucionis: Epigenetic modifications and cancer

Although all cells in our body have the same genome, they look different and perform different functions. Epigenetic modifications such as methylations ensure which sets of genes are expressed in specific cells and how this specificity is inherited. Cancer cells show particular epigenetic abnormalities which can be targeted for cancer therapies.

Ross Chapman: Repairing DNA damage

Whilst controlled DNA breaks allow for our vast repertoire of antibodies, DNA damage happening out of context can lead to cancer or predisposition to cancer. Recent developments in personalised medicine exploit the DNA repair weaknesses of cancer cells to selectively kill them. A better understanding of the underlying mechanisms can help develop innovative and targeted therapies.

John Christianson: Cleaning up misfolded proteins

Misfolded proteins can either create the loss of a cellular function, or escape degradation, causing aggregation diseases. Better knowledge of these mechanisms helps us understand the root cause of different kind of diseases, and also develop targets for therapeutic intervention.

Robert Gilbert: Targeting cancer mechanisms

Switching mechanisms within our cells are in part responsible for their development. MicroRNAs control a whole set of proteins associated with stem cell biology, particularly cancer stem cells. Targeting these components raises the potential for new anti-cancer therapeutics, which work by switching off protein production rather than inhibiting them later.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.